Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.

What It Covers

This meta-analysis looks at Semaglutide and Glucagon.

Research on semaglutide's effect on weight loss has been largely focused on Type 2 Diabetics.

Expanding the knowledge of semaglutide's outcome in non-diabetics may provide impactful changes at the clinical level.

Who the Included Studies Covered

The age groups tagged for this paper are adults.

How the Review Was Done

Academic Search Premier, Cumulative Index to Nursing and Allied Health Literature (CINAHL) complete, MEDLINE with Full Text, Cochrane Central Register of Controlled Trials, medrxiv.org, and clinicaltrials.gov were systematically investigated using a predetermined search strategy from inception to August 21, 2021.

Covidence.org was used to screen, select, and extract data by two independent reviewers.

Individual study bias was assessed using the Cochrane Risk of Bias 2 tool.

Data were exported to RevMan v5.4, where meta-analysis was conducted using a DerSimonian and Laird random-effects model.

What Was Measured

Expanding the knowledge of semaglutide's outcome in non-diabetics may provide impactful changes at the clinical level.

Topics PubMed links to this paper include Glucagon-Like Peptides, Hypoglycemic Agents, Obesity, Weight Loss and Semaglutide.

Author keywords: Anti-Obesity Agents, Glucagon-like peptide 1, Systematic review and meta-analysis.

What This Means in Plain Language

This is a meta-analysis of Semaglutide and Glucagon.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (International journal of clinical pharmacy), a journal based in Netherlands.

More context: the Semaglutide compound page and the Glucagon compound page, all human trials.